Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Genitourinary 1Breast 1

Conditions

Small Cell Lung Carcinoma 1Neoplasms 1Head and Neck Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Acrocephalosyndactylia 1

Interventions

pembrolizumab 20atezolizumab 8Nivolumab 8Docetaxel 7Carboplatin 6cemiplimab 5Immune Checkpoint Inhibitors 5Radiotherapy 4Paclitaxel 4Filgrastim 4Drug Therapy 4fludarabine 3durvalumab 3Radiosurgery 3Pemetrexed 3Gemcitabine 3Fluorouracil 3Cyclophosphamide 3Cisplatin 3Cetuximab 3Bortezomib 3niraparib 2motexafin gadolinium 2belinostat 2avelumab 2amminedichloro(2-methylpyridine)platinum(II) 2aldesleukin 2Tobacco Use Cessation Devices 2Tetrahydrouridine 2Taxes 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Head and Neck Neoplasms × Drug Combinations × Genitourinary × Clear all
NCT04125693 2022-04-01

Roll-over Study to Continue Treatment With the Investigational Drug Rogaratinib and to Further Test Its Safety

Bayer

Phase 2 Completed
1 enrolled
BreastGenitourinaryHead & NeckThoracic

Acrocephalosyndactylia, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡